Recent Finacing
Recent Raise
Tollys is a Lyon-based biopharma developing synthetic, 70-base-pair double-stranded RNA TLR3 agonist TL‑532 to modulate innate immunity, advancing preclinical and regulatory toxicology studies toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at Tollys.
